drugset
drugset / Trial / NCT07343635

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

NCT07343635 ↗

Recruiting 186 enrolled The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Non-randomizedParallel-groupDouble-blindTreatment

Summary

The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study

Timeline

Start
2026-02-01
Primary completion
2027-07-01
Completion
2027-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg Oral
Comparator Hydroxychloroquine Small molecule 200 mg Oral
Subject Tofacitinib Small molecule 5 mg Oral

Indications

rosacea